Drug Interaction Clinical Trial
Official title:
Effects of PPI Therapy on Clopidogrel-Induced Antiplatelet Effects: A Randomized Study
Clopidogrel, in combination with aspirin, is currently the recommended treatment for
secondary prevention of ischemic events in high-risk patients and for prevention of coronary
artery stent thrombosis. Patients receiving aspirin and clopidogrel are frequently treated
with proton pump inhibitors, such as omeprazole or pantoprazole, in order to prevent the
risk of gastrointestinal bleeding, accorded to guidelines. An interaction between proton
pump inhibitors and clopidogrel has been suggested, which may lead to a decrease of
clopidogrel effects. It remains unclear whether this interaction between PPIs and
clopidogrel might be a class effect or if this may be affected by timing regimen.
The objectives of this two-phase investigation are:
1. to compare clopidogrel platelet inhibitory effects when taken at the same time versus
separated at least 8 hours from omeprazole administration.
2. to compare clopidogrel-induced inhibitory effects when taken at the same time versus
staggered at least 8 hours from pantoprazole administration.
Clopidogrel, in combination with aspirin, is currently the recommended treatment for
secondary prevention of ischemic events in high-risk patients and for prevention of coronary
artery stent thrombosis. Patients receiving aspirin and clopidogrel are frequently treated
with proton pump inhibitors, such as omeprazole or pantoprazole, in order to prevent the
risk of gastrointestinal bleeding, accorded to guidelines. An interaction between proton
pump inhibitors and clopidogrel has been suggested, which may lead to a decrease of
clopidogrel effects. It remains unclear whether this interaction between PPIs and
clopidogrel might be a class effect or if this may be affected by timing regimen. The
objectives of this two-phase investigation are: 1. to compare clopidogrel platelet
inhibitory effects when taken at the same time versus separated at least 8 hours from
omeprazole administration. 2. to compare clopidogrel-induced inhibitory effects when taken
at the same time versus staggered at least 8 hours from pantoprazole administration. The
clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose,
starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and
pantoprazole at 80mg.
The proposed study will have a prospective, randomized, cross-over design. Subjects are
randomized in a 1:1 fashion to take PPI concomitantly (CONC regimen) or staggered by 8-12
hours (STAG regimen) for one-week on a background of clopidogrel therapy. In particular, in
the CONC regimen both drugs were taken in the morning, while in the STAG regimen clopidogrel
was taken in the morning and omeprazole in the evening. After a 2-4 week washout period,
subjects crossed-over treatment regimen. After completing these two treatment phases,
subjects underwent another washout period of 2-4 weeks and were treated for 1 week with
clopidogrel alone, without receiving omeprazole therapy (CLOP regimen). The sequence with
the PPI pantoprazole will have the same prospective, randomized, cross-over design as the
omeprazole sequence. A CLOP regimen in the absence of pantoprazole will be collected before
entering randomization phase with adequate wash-out period.
Blood sampling for platelet function assessments were performed at all three phases of the
study at the following time points: a) baseline, b) 24 hours after LD (before intake of
study medication), and c) 7 days (24 hours after the last MD).
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04645940 -
Fruquintinib Food Effect and Proton Pump Inhibitor Study
|
Phase 1 | |
Completed |
NCT04540965 -
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04531072 -
Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine
|
Phase 4 | |
Completed |
NCT03385525 -
Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074
|
Phase 1 | |
Completed |
NCT05680792 -
Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers
|
N/A | |
Completed |
NCT05137548 -
A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT05525351 -
The Application and Validation of Triple Drug Response Surface Models on Density Spectral Array in Clinical Anesthesia
|
||
Terminated |
NCT01980342 -
Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
|
Phase 4 | |
Completed |
NCT04080596 -
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin
|
Phase 1 | |
Recruiting |
NCT04593680 -
Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men
|
N/A | |
Active, not recruiting |
NCT04590417 -
Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women
|
N/A | |
Completed |
NCT05633147 -
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
|
Phase 1 | |
Completed |
NCT02391688 -
Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail
|
Phase 1 | |
Completed |
NCT00806299 -
Loperamide Grapefruit Juice Interaction PK Trial
|
Phase 1 | |
Completed |
NCT03336346 -
Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
|
||
Completed |
NCT04818086 -
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT03187015 -
A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
|
Phase 1 | |
Not yet recruiting |
NCT04463576 -
Drug Interactions in Hospital Information System. The PRoSIT System..
|
||
Not yet recruiting |
NCT03920566 -
The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
|
||
Completed |
NCT03011996 -
To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration
|
Phase 1 |